

=> d his

(FILE 'HOME' ENTERED AT 13:39:48 ON 14 APR 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
ENTERED AT

13:40:18 ON 14 APR 2002

L1 20380 S PHARMACEUTICAL COMPOSITION
L2 332 S SUCCINATE BUFFER
L3 1 S L1 (P) L2
L4 22052 S (HUMAN INSULIN-LIKE GROWTH FACTOR) OR (IGF-1)
L6 0 S L2 (P) L4
L7 2060 S SUCCINATE (P) BUFFER
L8 3 S L1 (P) L7
L9 3 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)
L10 2 S L9 NOT L3
L11 0 S L4 (P) L7

=> log y

\$

FILE 'HOME' ENTERED AT 13:39:48 ON 14 APR 2002

=> file medline caplus biosis embase scisearch agricola

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 13:40:18 ON 14 APR 2002

FILE 'CAPLUS' ENTERED AT 13:40:18 ON 14 APR 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:40:18 ON 14 APR 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 13:40:18 ON 14 APR 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 13:40:18 ON 14 APR 2002

COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 13:40:18 ON 14 APR 2002

=> s pharmaceutical composition

L1 20380 PHARMACEUTICAL COMPOSITION

=> s succinate buffer

L2 332 SUCCINATE BUFFER

=> s l1 (p) l2

L3 1 L1 (P) L2

=> d l3 1 ibib abs

L3 ANSWER 1 OF 1 CAPLUS .COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:62635 CAPLUS

DOCUMENT NUMBER: 112:62635

TITLE: Stabilized injection solutions containing
nonlyophilized gamma-interferons

INVENTOR(S): Hwang-Felgner, Jiin Yu; Jones, Richard E.; Maher,
James F.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8904177	A1	19890518	WO 1988-US3883	19881101
W: AU, DK, FI, HU, JP, KR, NO				
RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
IL 88233	A1	19930818	IL 1988-88233	19881030
AU 8827245	A1	19890601	AU 1988-27245	19881101
AU 621327	B2	19920312		
EP 386106	A1	19900912	EP 1988-910211	19881101
EP 386106	B1	19940302		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 03500882	T2	19910228	JP 1988-509401	19881101
JP 2732877	B2	19980330		
AT 102048	E	19940315	AT 1988-910211	19881101
ZA 8808249	A	19900725	ZA 1988-8249	19881103
DD 289470	A5	19910502	DD 1988-321429	19881103
CA 1335176	A1	19950411	CA 1988-582102	19881103
US 5151265	A	19920929	US 1990-514392	19900425
PRIORITY APPLN. INFO.:			US 1987-116434	19871103

AB A liq. ***pharmaceutical*** ***compn*** . comprises an effective
amt. of nonlyophilized .gamma.-interferon. The compn. further includes a
buffer capable of maintaining the pH within 4-6, polyhydric sugar alcs. as
stabilizer, and a nonionic detergent. The relative shelf-life for the
liq. contg. 2 mg/mL .gamma.-interferon, mannitol, and ***succinate***
buffer was 10 days as compared to 1 day for the lyophilized
formulation.

=> s (human insulin-like growth factor) or (IGF-1)

4 FILES SEARCHED...

L4 22052 (HUMAN INSULIN-LIKE GROWTH FACTOR) OR (IGF-1)

=> d his

(FILE 'HOME' ENTERED AT 13:39:48 ON 14 APR 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
13:40:18 ON 14 APR 2002

L1 20380 S PHARMACEUTICAL COMPOSITION

L2 332 S SUCCINATE BUFFER

L3 1 S L1 (P) L2

L4 22052 S (HUMAN INSULIN-LIKE GROWTH FACTOR) OR (IGF-1)

=> s 2 (p) 4

3 FILES SEARCHED...

L5 6261417 2 (P) 4

=> s l2 (p) l4

L6 0 L2 (P) L4

=> s succinate (p) buffer

L7 2060 SUCCINATE (P) BUFFER

=> s l1 (p) l7

L8 3 L1 (P) L7

=> duplicate remove l8

PROCESSING COMPLETED FOR L8

L9 3 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)

=> s l9 not l3

L10 2 L9 NOT L3

=> d l10 1-2 ibib abs

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:121156 CAPLUS

DOCUMENT NUMBER: 124:156044

TITLE: Pharmaceutical compositions containing hGH.

INVENTOR(S): Samaritani, Fabrizio

PATENT ASSIGNEE(S): Applied Research Systems, Neth.

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9535116	A1	19951228	WO 1994-IT86	19940617
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 804223	A1	19971105	EP 1994-920573	19940617
EP 804223	B1	19990922		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 10504531	T2	19980506	JP 1994-501903	19940617
AT 184798	E	19991015	AT 1994-920573	19940617
ES 2139081	T3	20000201	ES 1994-920573	19940617

US 5898030 A 19990427 US 1996-750684 19961217
PRIORITY APPLN. INFO.: EP 1994-920573 19940617
WO 1994-IT86 19940617

AB Pharmaceutical compns. contg. hGH were stabilized by saccharose. The formulation is particularly suitable for stabilizing a lyophilizate of recombinant hGH.

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:532058 CAPLUS

DOCUMENT NUMBER: 122:274053

TITLE: Process and apparatus for manufacturing of a pharmaceutical composition containing prednisolone sodium succinate, suitable for parenteral dosing
INVENTOR(S): Mago Karacsony, Erzsebet; Ambrus, Gabor; Balogh, Tibor; Danitz, Bela; Toldy, Lajos; Makk, Nandor; Tegdes, Aniko; Kovacs, Klara Maria; Bidlo, Gaborne; et al.

PATENT ASSIGNEE(S): Gyogyszerkutato Intezet, Hung.

SOURCE: Hung. Teljes, 14 pp.

CODEN: HUXXB

DOCUMENT TYPE: Patent

LANGUAGE: Hungarian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
HU 66012	A2	19940829	HU 1992-4081	19921222
HU 212306	B	19960528		

AB The process involves mixing prednisolone hemisuccinate and NaOH, sterile filtering of the resultant prednisolone sodium succinate soln., filling it into ampuls, lyophilizing it, and closing the ampuls under an inert gas atm. Thus, powd. prednisolone hemisuccinate with a particle size .ltoreq.200 .mu.m is dispersed in an aq. soln. contg. (9.5.+-.0.2):(0.5.+-.0.2) wt.:wt. Na2HPO4 and NaH2PO4 as buffer substances. The dispersion is cooled to 5-15.degree., preferably to 5-10.degree.. Then 80-95%, preferably 85-95%, of the stoichiometrically necessary 0.3-1.0% wt.:vol. NaOH soln. is added in portions during intensive stirring of the reaction medium and stirring is continued until the complete dissoln. of prednisolone hemisuccinate. A stainless steel reactor for carrying out the process is also claimed. In contrast to former processes this process gives only trace amts. of hydrolysis products at most.

=> d his

(FILE 'HOME' ENTERED AT 13:39:48 ON 14 APR 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:40:18 ON 14 APR 2002

L1 20380 S PHARMACEUTICAL COMPOSITION
L2 332 S SUCCINATE BUFFER
L3 1 S L1 (P) L2
L4 22052 S (HUMAN INSULIN-LIKE GROWTH FACTOR) OR (IGF-1)
L5 6261417 S 2 (P) 4
L6 0 S L2 (P) L4
L7 2060 S SUCCINATE (P) BUFFER
L8 3 S L1 (P) L7
L9 3 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)
L10 2 S L9 NOT L3

=> s 14 (p) 17

L11 0 L4 (P) L7

=> d his

(FILE 'HOME' ENTERED AT 13:39:48 ON 14 APR 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 13:40:18 ON 14 APR 2002

L1 20380 S PHARMACEUTICAL COMPOSITION
L2 332 S SUCCINATE BUFFER

L3 1 S L1 (P) L2
 L4 22052 S (HUMAN INSULIN-CE GROWTH FACTOR) OR (IGF-1)
 L5 6261417 S 2 (P) 4
 L6 0 S L2 (P) L4
 L7 2060 S SUCCINATE (P) BUFFER
 L8 3 S L1 (P) L7
 L9 3 DUPLICATE REMOVE L8 (0 DUPLICATES REMOVED)
 L10 2 S L9 NOT L3
 L11 0 S L4 (P) L7

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	38.28	38.49
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.86	-1.86

STN INTERNATIONAL LOGOFF AT 13:45:32 ON 14 APR 2002